<DOC>
	<DOCNO>NCT03049306</DOCNO>
	<brief_summary>The primary objective study test whether propranolol lower glucose free fatty acid level sleep obstructive sleep apnea ( OSA ) , preserve vascular function ( EndoPAT ) versus placebo . The secondary objective test whether propranolol influence sleep quality , architecture , hemodynamics OSA . OSA elicit temporarily discontinue CPAP therapy patient history OSA accustom CPAP therapy ( CPAP withdrawal ) .</brief_summary>
	<brief_title>Propranolol Sleep Apnea Therapy</brief_title>
	<detailed_description>Free fatty acid glucose elevation occur night obstructive sleep apnea ( OSA ) patient , elevation may responsible adverse cardio-metabolic consequence OSA . The sympathetic nervous system well know mediate adipose tissue lipolysis well `` stress hyperglycemia '' . Thus , investigator may able mitigate nocturnal metabolic change beta adrenergic blockade . Propranolol non-selective beta blocker use variety indication include hypertension anxiety . In study investigator administer propranolol placebo patient OSA sleep . Investigators compare nocturnal metabolic profile hemodynamics on/off propranolol set CPAP withdrawal .</detailed_description>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>History OSA ( AHI &gt; 20 , &gt; 50 % event obstructive ) Accustomed CPAP use , willing discontinue CPAP temporarily study . If participant already complete `` Metabolic Impact Intermittent CPAP '' ( NA_00086830 ) , must exhibit &gt; 10 % increase nocturnal FFA glucose CPAP Cardiovascular risk Decompensated congestive heart failure Atrial fibrillation , sick sinus syndrome , 2nd 3rd degree heart block , pacemaker implantation , WolffParkinsonWhite Syndrome ( know , check screen EKG ) Uncontrolled hypertension &gt; 170/110 History postural hypotension . Resting systolic pressure &lt; 90 heart rate &lt; 50 screen visit Drug interaction currently take follow drug . ( Subjects medication exclude participation drug question discontinue purpose participation study . ) Calcium channel blocker reduce heart rate ( diltiazem , verapamil , fendiline , gallopamil ) Sympatholytic drug : beta blocker ; clonidine , terazosin doxazosin ; reserpine Antiarrhythmic drug : ( e.g . amiodarone , sotalol , digoxin , quinidine , lidocaine , propafenone ) Coumadin ( propranolol may prolong INR ) Drugs Inhibit CYP2D6 , CYP1A2 , CYP2C19 : amiodarone , ciprofloxacin , cimetidine , delavirdine , fluconazole , fluoxetine , fluvoxamine , imipramine , isoniazid , paroxetine , quinidine , ritonavir , rizatriptan , teniposide , theophylline , tolbutamide , zileuton , zolmitriptan Drugs increase hepatic metabolism propranolol : rifampin , ethanol , phenytoin , phenobarbital Neuroleptics/anxiolytics : ( thioridazine , chlorpromazine may increase propranolol level ) , haloperidol , valium Illicit drug cocaine amphetamine . Other medical condition Sleep disorder OSA , include : restless leg syndrome , parasomnia , narcolepsy . Shift work circadian rhythm disorder expect prevent good sleep schedule protocol Insulindependent diabetes mellitus Myasthenia gravis Pheochromocytoma Uncontrolled bronchospastic lung disease asthma chronic obstructive pulmonary disease ( COPD ) Current smoke Chronic renal liver failure Known pregnancy , urine test woman childbearing age ; nursing mother Known hypersensitivity beta blocker Commercial driver pilot without ability avoid duty CPAP withdrawal period .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Obstructive sleep apnea</keyword>
	<keyword>CPAP</keyword>
	<keyword>Propranolol</keyword>
	<keyword>Metabolism</keyword>
</DOC>